Oragenics Financials
Financial Health Signals
Oragenics passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
For every $1 of reported earnings, Oragenics generates $0.81 in operating cash flow (-$8.6M OCF vs -$10.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Oragenics earns $-354.0 in operating income for every $1 of interest expense (-$10.6M vs $30K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
This page shows Oragenics (OGEN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Oragenics reported -$10.6M in net income in fiscal year 2024. This represents an increase of 48.8% from the prior year.
Oragenics earned $-1.60 per diluted share (EPS) in fiscal year 2024. This represents an increase of 82.6% from the prior year.
Oragenics held $865K in cash against $0 in long-term debt as of fiscal year 2024.
Oragenics had 419,003 shares outstanding in fiscal year 2024. This represents a decrease of 86.4% from the prior year.
Oragenics invested $4.1M in research and development in fiscal year 2024. This represents a decrease of 73.4% from the prior year.
OGEN Income Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | $0-100.0% | $7K-43.3% | $13K-22.7% | $17K | $0-100.0% | $86K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $931K+5.9% | $879K-92.0% | $11.0M+1335.2% | $769K-61.7% | $2.0M+20.0% | $1.7M+18.5% | $1.4M-49.2% | $2.8M |
| SG&A Expenses | $2.2M+40.7% | $1.6M-11.2% | $1.8M+31.7% | $1.3M+19.4% | $1.1M-10.7% | $1.2M+40.6% | $888K-26.9% | $1.2M |
| Operating Income | -$3.1M-28.2% | -$2.4M+81.0% | -$12.8M-511.0% | -$2.1M+32.6% | -$3.1M-7.0% | -$2.9M-26.3% | -$2.3M+41.1% | -$3.9M |
| Interest Expense | $7K-29.4% | $10K-18.5% | $12K-13.7% | $14K+1580.9% | $843-74.8% | $3K-42.4% | $6K+11.2% | $5K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$3.1M-24.5% | -$2.5M+80.7% | -$12.7M-533.3% | -$2.0M+34.0% | -$3.1M-7.2% | -$2.8M-27.1% | -$2.2M+42.2% | -$3.9M |
| EPS (Diluted) | $-1.96 | $-11.32 | $-5.41-536.5% | $-0.85+43.7% | $-1.51-7.1% | $-1.41 | N/A | $-1.99 |
OGEN Balance Sheet
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $12.7M+762.8% | $1.5M-70.4% | $5.0M-37.1% | $7.9M-6.7% | $8.5M-30.2% | $12.1M-17.8% | $14.8M-13.4% | $17.1M |
| Current Assets | $12.7M+762.8% | $1.5M-61.9% | $3.9M-50.5% | $7.8M-3.5% | $8.1M-30.8% | $11.7M-18.1% | $14.3M-13.5% | $16.5M |
| Cash & Equivalents | $11.4M+1218.6% | $865K-75.2% | $3.5M-39.6% | $5.8M-10.9% | $6.5M-29.3% | $9.2M-19.9% | $11.4M-18.1% | $14.0M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $2.9M+70.6% | $1.7M-6.3% | $1.8M+28.2% | $1.4M+16.2% | $1.2M-36.0% | $1.9M+7.8% | $1.7M-1.6% | $1.8M |
| Current Liabilities | N/A | N/A | $1.8M+28.2% | $1.4M+22.9% | $1.1M-35.9% | $1.8M+11.5% | $1.6M+1.5% | $1.6M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $9.8M+4740.0% | -$212K-106.7% | $3.2M-51.2% | $6.5M-10.5% | $7.3M-29.2% | $10.2M-21.3% | $13.0M-14.8% | $15.3M |
| Retained Earnings | -$224.3M-3.5% | -$216.8M-5.1% | -$206.2M-6.6% | -$193.5M-1.1% | -$191.5M-1.6% | -$188.4M-1.5% | -$185.6M-1.2% | -$183.3M |
OGEN Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.0M-47.9% | -$2.0M-83.1% | -$1.1M+26.6% | -$1.5M+41.7% | -$2.6M-22.2% | -$2.1M+13.3% | -$2.4M+35.6% | -$3.8M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | $3K-90.7% | $37K |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | -$2.4M+36.1% | -$3.8M |
| Investing Cash Flow | N/A | N/A | -$1000K | N/A | N/A | N/A | -$3K+90.7% | -$37K |
| Financing Cash Flow | $12.4M+4859.2% | -$261K-44.4% | -$181K-124.7% | $732K+778.6% | -$108K+32.5% | -$160K-81.5% | -$88K+15.0% | -$104K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
OGEN Financial Ratios
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | -28053.1%-4431.5pp | -23621.7%-6558.6pp | -17063.1% | N/A | -4540.0% |
| Net Margin | N/A | N/A | N/A | -26960.7%-3785.2pp | -23175.5%-6464.7pp | -16710.7% | N/A | -4497.7% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -24.1%+23.2pp | -47.3%+209.4pp | -256.7%-231.2pp | -25.5%+10.6pp | -36.0%-12.6pp | -23.4%-8.3pp | -15.2%+7.5pp | -22.7% |
| Current Ratio | N/A | N/A | 2.15-3.4 | 5.57-1.5 | 7.10+0.5 | 6.57-2.4 | 8.95-1.6 | 10.50 |
| Debt-to-Equity | 0.29+8.2 | -7.95-8.5 | 0.57+0.4 | 0.22+0.0 | 0.17-0.0 | 0.18+0.0 | 0.13+0.0 | 0.12 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -4431.2% |
Note: Shareholder equity is negative (-$212K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Frequently Asked Questions
Is Oragenics profitable?
No, Oragenics (OGEN) reported a net income of -$10.6M in fiscal year 2024.
What is Oragenics's earnings per share (EPS)?
Oragenics (OGEN) reported diluted earnings per share of $-1.60 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Oragenics's operating cash flow?
Oragenics (OGEN) generated -$8.6M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Oragenics's total assets?
Oragenics (OGEN) had $1.5M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Oragenics spend on research and development?
Oragenics (OGEN) invested $4.1M in research and development during fiscal year 2024.
How many shares does Oragenics have outstanding?
Oragenics (OGEN) had 419,003 shares outstanding as of fiscal year 2024.
What is Oragenics's debt-to-equity ratio?
Oragenics (OGEN) had a debt-to-equity ratio of -7.95 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Oragenics's return on assets (ROA)?
Oragenics (OGEN) had a return on assets of -717.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Oragenics's cash runway?
Based on fiscal year 2024 data, Oragenics (OGEN) had $865K in cash against an annual operating cash burn of $8.6M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Oragenics's debt-to-equity ratio negative or unusual?
Oragenics (OGEN) has negative shareholder equity of -$212K as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Oragenics's Piotroski F-Score?
Oragenics (OGEN) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Oragenics's earnings high quality?
Oragenics (OGEN) has an earnings quality ratio of 0.81x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Oragenics cover its interest payments?
Oragenics (OGEN) has an interest coverage ratio of -354.0x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.